News

Syngenta is on a shopping spree
Enlarge image

BusinessSwitzerlandBelgiumGermany

Syngenta is on a shopping spree

24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences.

Syngenta announced an offer to acquire all outstanding shares of Devgen NV at a price of €16 in cash per share, valuing the Belgian hybrid rice seed producer at €403m in total. The offer price represents a premium of 70% to Devgen's closing price on NYSE Euronext Brussels on 20 September 2012, the day before the tender offer was made public. 

The Belgian group posted sales of €25.5m and an operational loss of €6.3m in 2011. Created in 1997, the company employs 250 people and among its products is a hybrid rice developed for India and South-east Asia. The asset will have a “very significant impact” on Syngenta’s $500 million rice business, Chief Operating Officer Davor Pisk said in an interview today. "We are also buying their competence in RNAi technology which are relevant for us across a broad range of crops“, added Syngenta spokeswoman Jennifer Gough.

This is Syngenta's second deal announced within a week. Only days before, Swiss company revealed its plans to acquire Pasteuria Biosciences for €87m. Since 2011, Syngenta and the US company have had an exclusive global technology partnership to develop and commercialise biological products to control plant-parasitic nematodes, using the naturally occurring soil bacteria Pasteuria spp.

With its acquisition strategy, Syngenta reacts to the increasingly fierce competition with agribusiness companies Bayer and BASF both of Germany. BASF recently announced the intention to buy Becker Underwood for €785m, while Bayer decided months ago to purchase US-based AgraQuest for €340m plus milestone payments.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-03/syngenta-is-on-a-shopping-spree.html

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • EPIGENOMICS3.78 EUR11.83%
  • MOLOGEN7.75 EUR6.02%

FLOP

  • SANTHERA92.70 CHF-7.39%
  • MEDIGENE4.40 EUR-2.87%
  • ADDEX3.82 CHF-2.80%

TOP

  • SANTHERA92.70 CHF54.8%
  • EPIGENOMICS3.78 EUR18.1%
  • BB BIOTECH143.70 EUR11.1%

FLOP

  • WILEX2.40 EUR-11.1%
  • BIOFRONTERA2.40 EUR-10.4%
  • VITA 343.77 EUR-9.4%

TOP

  • SANTHERA92.70 CHF3965.8%
  • CO.DON2.45 EUR184.9%
  • PAION2.38 EUR158.7%

FLOP

  • CYTOS0.26 CHF-93.7%
  • MEDIGENE4.40 EUR-70.1%
  • MERCK KGAA66.43 EUR-42.9%

No liability assumed, Date: 01.09.2014